Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck (MRK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $76.53 in the latest trading session, marking a +0.18% move from the prior day.

Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Healthcare ETFs in Focus as Q2 Earnings Unfold

by Sweta Killa

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Merck (MRK) Heart Failure Drug Verquvo Gets Approval in Europe

by Zacks Equity Research

Merck (MRK)/Bayer's (BAYRY) vericiguat gets approval for symptomatic chronic heart failure in patients with reduced ejection fraction in Europe.

Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.

J&J (JNJ) Beats on Q2 Earnings & Sales, Ups View, Stock Rises

by Zacks Equity Research

J&J (JNJ) beats second-quarter 2021 estimates for both earnings and sales. It raises its financial expectations for the year. It forecasts $2.5 billion in 2021 sales of COVID-19 vaccine.

Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study

by Zacks Equity Research

Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.

Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance

by Zacks Equity Research

Merck's (MRK) 15-valent pneumococcal conjugate vaccine, Vaxneuvance includes pneumococcal serotypes, 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

New Strong Sell Stocks for July 19th

by Zacks Equity Research

GPL, MRK, OBLG, POST, and QUMU have been added to the Zacks Rank #5 (Strong Sell) List on July 19, 2021

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $78.02, moving +0.15% from the previous trading session.

Kinjel Shah headshot

Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall

by Kinjel Shah

Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $77.90, marking a +0.36% move from the previous day.

Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data

by Zacks Equity Research

Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.

Seagen (SGEN) Gets Regular Approval, Label Expansion for Padcev

by Zacks Equity Research

Seagen and Astellas' two sBLAs for Padcev get FDA approval for patients with locally advanced or metastatic urothelial cancer. The approval comes one month before the PDUFA date of Aug 17, 2021.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $78.01 in the latest trading session, marking a -0.14% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates

by Kinjel Shah

Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)

Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer

by Zacks Equity Research

Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.

Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?

by Zacks Equity Research

Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.

Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda

by Zacks Equity Research

Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to RHHBY, MRK Drugs, FDA and Pipeline Updates

by Kinjel Shah

EU approves Roche's (RHHBY) Enspryng and Merck's (MRK) Keytruda for a new indication. FDA grants EUA to Roche's Actemra for COVID-19.

Merck (MRK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $77.99, marking a +0.28% move from the previous day.

Alpine (ALPN) Enters Immuno-Oncology Collaboration With Merck

by Zacks Equity Research

Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.

Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU (Revised)

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study

Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy

by Zacks Equity Research

Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.

Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study